drugset / Trial / NCT01431053

Study of Aspirin and Exemestane as Adjuvant Treatment in Breast Cancer

NCT01431053

Phase 2 Unknown 160 enrolled Chinese Academy of Medical Sciences
RandomizedParallel-groupOpen-labelPrevention

Summary

This is a phase II study to assess efficacy/safety of Exemestane with or without Aspirin as the adjuvant treatment in postmenopausal breast cancer patients.

Timeline

Start
2011-07
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 50 mg Oral
Subject Exemestane Small molecule 25 mg Oral

Indications